This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
Working with individual set: LUSC.
Number of patients in set: 178
The input for this pipeline is a set of individuals with the following files associated for each:
1. An annotated .maf file describing the mutations called for the respective individual, and their properties.
2. A .wig file that contains information about the coverage of the sample.
MAF used for this analysis: LUSC.final_analysis_set.maf
Significantly mutated genes (q ≤ 0.1): 142
Mutations seen in COSMIC: 351
Significantly mutated genes in COSMIC territory: 11
Genes with clustered mutations (≤ 3 aa apart): 0
Significantly mutated genesets: 22
Significantly mutated genesets: (excluding sig. mutated genes): 0
Read 178 MAFs of type "Broad"
Total number of mutations in input MAFs: 112274
After removing 5 mutations outside chr1-24: 112269
After removing 48505 noncoding mutations: 63764
After collapsing adjacent/redundant mutations: 62900
Number of mutations before filtering: 62900
After removing 361 mutations outside gene set: 62539
After removing 32 mutations outside category set: 62507
Table 1. Get Full Table Table representing breakdown of mutations by type.
| type | count |
|---|---|
| Frame_Shift_Del | 521 |
| Frame_Shift_Ins | 134 |
| In_Frame_Del | 84 |
| In_Frame_Ins | 19 |
| Missense_Mutation | 41821 |
| Nonsense_Mutation | 3567 |
| Nonstop_Mutation | 55 |
| Silent | 15131 |
| Splice_Site | 1152 |
| Translation_Start_Site | 23 |
| Total | 62507 |
Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.
| category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
|---|---|---|---|---|---|---|
| Tp*C->mut | 12931 | 705628846 | 0.000018 | 18 | 2.1 | 3.3 |
| (A/C/G)p*C->(A/T) | 16706 | 2005408876 | 8.3e-06 | 8.3 | 0.94 | 2.6 |
| (A/C/G)p*C->G | 3292 | 2005408876 | 1.6e-06 | 1.6 | 0.18 | 4.9 |
| A->mut | 8807 | 2607765148 | 3.4e-06 | 3.4 | 0.38 | 3.9 |
| indel+null | 5610 | 5318802870 | 1.1e-06 | 1.1 | 0.12 | NaN |
| double_null | 30 | 5318802870 | 5.6e-09 | 0.0056 | 0.00063 | NaN |
| Total | 47376 | 5318802870 | 8.9e-06 | 8.9 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
Figure 1.
Figure 2. Patients counts and rates file used to generate this plot: LUSC.patients.counts_and_rates.txt
Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.
Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 142. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).
| rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ns_s | p_ks | p_cons | p_joint | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TP53 | tumor protein p53 | 223924 | 144 | 140 | 96 | 4 | 8 | 39 | 18 | 32 | 47 | 0 | <1.00e-15 | 6.7e-11 | 2e-07 | 2e-07 | 0 | <1.00e-15 | <4.52e-12 |
| 2 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 318442 | 28 | 27 | 15 | 0 | 19 | 4 | 0 | 4 | 1 | 0 | <1.00e-15 | 0.0071 | 2e-07 | 2e-07 | 0 | <1.00e-15 | <4.52e-12 |
| 3 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 585086 | 29 | 27 | 16 | 1 | 20 | 4 | 0 | 5 | 0 | 0 | 1.40e-12 | 0.021 | 0.000071 | 0.00075 | 0 | <1.00e-15 | <4.52e-12 |
| 4 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 175686 | 26 | 26 | 23 | 1 | 5 | 5 | 2 | 2 | 12 | 0 | <1.00e-15 | 0.02 | 0.0015 | 2.2e-06 | 0 | <1.00e-15 | <4.52e-12 |
| 5 | TPTE | transmembrane phosphatase with tensin homology | 309720 | 30 | 24 | 29 | 2 | 10 | 4 | 2 | 9 | 5 | 0 | <1.00e-15 | 0.034 | 0.61 | 0.32 | 0.45 | <1.62e-14 | <5.87e-11 |
| 6 | KEAP1 | kelch-like ECH-associated protein 1 | 325562 | 23 | 21 | 21 | 0 | 9 | 8 | 2 | 2 | 2 | 0 | 1.09e-12 | 0.00032 | 0.046 | 0.21 | 0.066 | 2.25e-12 | 6.77e-09 |
| 7 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 222144 | 16 | 14 | 15 | 0 | 4 | 1 | 0 | 3 | 8 | 0 | 8.46e-12 | 0.11 | 0.037 | 0.37 | 0.064 | 1.59e-11 | 4.10e-08 |
| 8 | SI | sucrase-isomaltase (alpha-glucosidase) | 1009616 | 46 | 36 | 46 | 2 | 10 | 21 | 2 | 8 | 5 | 0 | 6.77e-13 | 0.0067 | 0.76 | 0.79 | 0.94 | 1.84e-11 | 4.17e-08 |
| 9 | TRIM58 | tripartite motif-containing 58 | 197936 | 15 | 15 | 15 | 1 | 2 | 8 | 1 | 1 | 3 | 0 | 1.81e-10 | 0.053 | 0.11 | 0.54 | 0.2 | 9.03e-10 | 1.82e-06 |
| 10 | ELTD1 | EGF, latrophilin and seven transmembrane domain containing 1 | 375046 | 18 | 18 | 18 | 1 | 4 | 3 | 1 | 4 | 6 | 0 | 1.52e-10 | 0.081 | 0.47 | 0.76 | 0.67 | 2.45e-09 | 4.43e-06 |
| 11 | FAM5C | family with sequence similarity 5, member C | 414562 | 28 | 27 | 28 | 3 | 3 | 15 | 1 | 9 | 0 | 0 | 1.31e-10 | 0.043 | 1 | 0.96 | 1 | 3.10e-09 | 5.10e-06 |
| 12 | OR5L2 | olfactory receptor, family 5, subfamily L, member 2 | 167320 | 15 | 13 | 15 | 1 | 0 | 6 | 3 | 5 | 1 | 0 | 3.03e-10 | 0.068 | 0.41 | 0.39 | 0.49 | 3.49e-09 | 5.25e-06 |
| 13 | REG1B | regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) | 92738 | 11 | 11 | 9 | 1 | 6 | 2 | 0 | 2 | 1 | 0 | 1.26e-09 | 0.2 | 0.35 | 0.12 | 0.2 | 5.96e-09 | 8.26e-06 |
| 14 | ZBBX | zinc finger, B-box domain containing | 440550 | 17 | 17 | 17 | 1 | 4 | 4 | 1 | 5 | 3 | 0 | 7.36e-09 | 0.13 | 0.023 | 0.65 | 0.038 | 6.39e-09 | 8.26e-06 |
| 15 | LRRC4C | leucine rich repeat containing 4C | 343006 | 19 | 17 | 19 | 1 | 5 | 8 | 1 | 4 | 1 | 0 | 1.01e-08 | 0.021 | 0.073 | 0.17 | 0.075 | 1.67e-08 | 0.000020 |
| 16 | CYP11B1 | cytochrome P450, family 11, subfamily B, polypeptide 1 | 275544 | 15 | 15 | 15 | 1 | 0 | 11 | 1 | 3 | 0 | 0 | 4.15e-09 | 0.031 | 0.094 | 0.9 | 0.2 | 1.79e-08 | 0.000020 |
| 17 | OR4M2 | olfactory receptor, family 4, subfamily M, member 2 | 168388 | 14 | 14 | 14 | 2 | 2 | 6 | 0 | 5 | 1 | 0 | 1.68e-09 | 0.2 | 0.93 | 0.8 | 1 | 3.57e-08 | 0.000038 |
| 18 | DPPA4 | developmental pluripotency associated 4 | 167854 | 12 | 12 | 12 | 0 | 4 | 3 | 1 | 0 | 4 | 0 | 1.23e-08 | 0.057 | 0.31 | 0.46 | 0.32 | 8.04e-08 | 0.000081 |
| 19 | OR2G6 | olfactory receptor, family 2, subfamily G, member 6 | 169990 | 15 | 15 | 15 | 3 | 3 | 5 | 0 | 7 | 0 | 0 | 9.00e-08 | 0.22 | 0.042 | 0.34 | 0.067 | 1.21e-07 | 0.00011 |
| 20 | KRTAP5-5 | keratin associated protein 5-5 | 120684 | 9 | 9 | 6 | 1 | 0 | 3 | 1 | 0 | 5 | 0 | 1.17e-07 | 0.53 | 0.02 | 1 | 0.053 | 1.23e-07 | 0.00011 |
| 21 | CRB1 | crumbs homolog 1 (Drosophila) | 759882 | 27 | 23 | 27 | 2 | 8 | 6 | 1 | 9 | 3 | 0 | 3.54e-08 | 0.043 | 0.14 | 0.81 | 0.27 | 1.88e-07 | 0.00016 |
| 22 | ASB5 | ankyrin repeat and SOCS box-containing 5 | 181204 | 9 | 9 | 9 | 0 | 3 | 1 | 3 | 2 | 0 | 0 | 0.000012 | 0.14 | 0.013 | 0.0034 | 0.00083 | 1.97e-07 | 0.00016 |
| 23 | PDYN | prodynorphin | 137594 | 8 | 8 | 8 | 0 | 2 | 3 | 2 | 1 | 0 | 0 | 0.000020 | 0.09 | 0.0005 | 0.33 | 0.00063 | 2.44e-07 | 0.00019 |
| 24 | OR6F1 | olfactory receptor, family 6, subfamily F, member 1 | 165718 | 13 | 13 | 13 | 2 | 2 | 6 | 1 | 4 | 0 | 0 | 1.11e-07 | 0.19 | 0.32 | 0.14 | 0.18 | 3.78e-07 | 0.00028 |
| 25 | ESRRG | estrogen-related receptor gamma | 250090 | 12 | 12 | 12 | 1 | 2 | 5 | 1 | 2 | 2 | 0 | 5.26e-07 | 0.13 | 0.082 | 0.5 | 0.12 | 1.15e-06 | 0.00083 |
| 26 | USP29 | ubiquitin specific peptidase 29 | 493594 | 18 | 17 | 18 | 1 | 3 | 6 | 2 | 4 | 3 | 0 | 9.47e-08 | 0.075 | 0.85 | 0.24 | 0.81 | 1.34e-06 | 0.00093 |
| 27 | CFHR4 | complement factor H-related 4 | 181560 | 10 | 10 | 10 | 1 | 0 | 4 | 1 | 3 | 2 | 0 | 2.71e-07 | 0.35 | 0.41 | 0.36 | 0.44 | 2.04e-06 | 0.0014 |
| 28 | C20orf26 | chromosome 20 open reading frame 26 | 679426 | 21 | 19 | 21 | 1 | 4 | 11 | 1 | 3 | 2 | 0 | 3.86e-06 | 0.017 | 0.025 | 0.36 | 0.048 | 3.08e-06 | 0.0020 |
| 29 | SLC13A1 | solute carrier family 13 (sodium/sulfate symporters), member 1 | 328944 | 12 | 12 | 12 | 1 | 4 | 2 | 1 | 4 | 1 | 0 | 1.67e-06 | 0.15 | 0.066 | 0.51 | 0.12 | 3.27e-06 | 0.0020 |
| 30 | REG3G | regenerating islet-derived 3 gamma | 97544 | 8 | 8 | 8 | 1 | 1 | 3 | 0 | 0 | 4 | 0 | 4.32e-07 | 0.26 | 0.45 | 0.42 | 0.64 | 4.48e-06 | 0.0027 |
| 31 | CPS1 | carbamoyl-phosphate synthetase 1, mitochondrial | 832506 | 27 | 24 | 26 | 2 | 4 | 14 | 1 | 6 | 2 | 0 | 1.44e-06 | 0.025 | 0.13 | 0.9 | 0.21 | 4.88e-06 | 0.0028 |
| 32 | MAGEB2 | melanoma antigen family B, 2 | 129406 | 9 | 9 | 9 | 1 | 2 | 4 | 2 | 1 | 0 | 0 | 5.14e-07 | 0.27 | 0.67 | 0.62 | 0.74 | 6.04e-06 | 0.0033 |
| 33 | OR51B2 | olfactory receptor, family 51, subfamily B, member 2 | 167854 | 10 | 10 | 10 | 0 | 2 | 3 | 1 | 3 | 1 | 0 | 8.16e-07 | 0.077 | 0.37 | 0.36 | 0.47 | 6.05e-06 | 0.0033 |
| 34 | PNLIPRP3 | pancreatic lipase-related protein 3 | 258456 | 11 | 11 | 11 | 1 | 1 | 5 | 2 | 1 | 2 | 0 | 2.52e-06 | 0.38 | 0.14 | 0.22 | 0.17 | 6.58e-06 | 0.0034 |
| 35 | SPANXN1 | SPANX family, member N1 | 40406 | 5 | 5 | 5 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 2.14e-06 | 0.32 | 0.13 | 0.33 | 0.2 | 6.63e-06 | 0.0034 |
Figure S1. This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.
Figure S2. This figure depicts the distribution of mutations and mutation types across the NFE2L2 significant gene.
Figure S3. This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.
Figure S4. This figure depicts the distribution of mutations and mutation types across the CDKN2A significant gene.
Figure S5. This figure depicts the distribution of mutations and mutation types across the TPTE significant gene.
Figure S6. This figure depicts the distribution of mutations and mutation types across the KEAP1 significant gene.
Figure S7. This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.
Figure S8. This figure depicts the distribution of mutations and mutation types across the SI significant gene.
Figure S9. This figure depicts the distribution of mutations and mutation types across the TRIM58 significant gene.
Figure S10. This figure depicts the distribution of mutations and mutation types across the ELTD1 significant gene.
Figure S11. This figure depicts the distribution of mutations and mutation types across the FAM5C significant gene.
Figure S12. This figure depicts the distribution of mutations and mutation types across the OR5L2 significant gene.
Figure S13. This figure depicts the distribution of mutations and mutation types across the REG1B significant gene.
Figure S14. This figure depicts the distribution of mutations and mutation types across the ZBBX significant gene.
Figure S15. This figure depicts the distribution of mutations and mutation types across the LRRC4C significant gene.
Figure S16. This figure depicts the distribution of mutations and mutation types across the CYP11B1 significant gene.
Figure S17. This figure depicts the distribution of mutations and mutation types across the OR4M2 significant gene.
Figure S18. This figure depicts the distribution of mutations and mutation types across the DPPA4 significant gene.
Figure S19. This figure depicts the distribution of mutations and mutation types across the OR2G6 significant gene.
Figure S20. This figure depicts the distribution of mutations and mutation types across the KRTAP5-5 significant gene.
Figure S21. This figure depicts the distribution of mutations and mutation types across the CRB1 significant gene.
Figure S22. This figure depicts the distribution of mutations and mutation types across the ASB5 significant gene.
Figure S23. This figure depicts the distribution of mutations and mutation types across the OR6F1 significant gene.
Figure S24. This figure depicts the distribution of mutations and mutation types across the ESRRG significant gene.
Figure S25. This figure depicts the distribution of mutations and mutation types across the USP29 significant gene.
Figure S26. This figure depicts the distribution of mutations and mutation types across the CFHR4 significant gene.
Figure S27. This figure depicts the distribution of mutations and mutation types across the C20orf26 significant gene.
Figure S28. This figure depicts the distribution of mutations and mutation types across the SLC13A1 significant gene.
Figure S29. This figure depicts the distribution of mutations and mutation types across the REG3G significant gene.
Figure S30. This figure depicts the distribution of mutations and mutation types across the CPS1 significant gene.
Figure S31. This figure depicts the distribution of mutations and mutation types across the MAGEB2 significant gene.
Figure S32. This figure depicts the distribution of mutations and mutation types across the OR51B2 significant gene.
Figure S33. This figure depicts the distribution of mutations and mutation types across the PNLIPRP3 significant gene.
Note:
N - number of sequenced bases in this gene across the individual set.
n - number of (nonsilent) mutations in this gene across the individual set.
npat - number of patients (individuals) with at least one nonsilent mutation.
nsite - number of unique sites having a non-silent mutation.
nsil - number of silent mutations in this gene across the individual set.
n1 - number of nonsilent mutations of type: Tp*C->mut .
n2 - number of nonsilent mutations of type: (A/C/G)p*C->(A/T) .
n3 - number of nonsilent mutations of type: (A/C/G)p*C->G .
n4 - number of nonsilent mutations of type: A->mut .
n5 - number of nonsilent mutations of type: indel+null .
null - mutation category that includes nonsense, frameshift, splice-site mutations
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
p = p-value (overall)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 11. Number of genes displayed: 10
| rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 29 | 184 | 24 | 32752 | 9572 | 1.2e-12 | 2.5e-09 |
| 2 | TP53 | tumor protein p53 | 144 | 308 | 141 | 54824 | 25449 | 1.7e-12 | 2.5e-09 |
| 3 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 26 | 315 | 25 | 56070 | 559 | 1.7e-12 | 2.5e-09 |
| 4 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 16 | 728 | 16 | 129584 | 579 | 2.2e-12 | 2.5e-09 |
| 5 | FBXW7 | F-box and WD repeat domain containing 7 | 11 | 91 | 6 | 16198 | 220 | 1.1e-08 | 1e-05 |
| 6 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 4 | 19 | 4 | 3382 | 802 | 3.3e-08 | 0.000025 |
| 7 | RB1 | retinoblastoma 1 (including osteosarcoma) | 12 | 267 | 7 | 47526 | 17 | 3.3e-07 | 0.00022 |
| 8 | HEPACAM2 | 4 | 1 | 2 | 178 | 2 | 1.2e-06 | 0.00071 | |
| 9 | NF1 | neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) | 22 | 285 | 6 | 50730 | 21 | 8e-06 | 0.004 |
| 10 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 8 | 88 | 4 | 15664 | 77 | 0.000014 | 0.0064 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
There were no clustered mutations discovered.
Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 22. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ABL1(3), ATM(8), ATR(13), CCNA1(1), CCND1(1), CCNE1(3), CDKN1A(2), CDKN2A(26), CDKN2B(1), E2F1(2), HDAC1(2), RB1(12), SKP2(2), TFDP1(3), TGFB1(1), TGFB2(3), TP53(144) | 8137626 | 227 | 156 | 176 | 13 | 28 | 65 | 23 | 40 | 71 | 0 | 5.9e-11 | <1.00e-15 | <5.13e-14 |
| 2 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | ABL1(3), CDKN2A(26), E2F1(2), MDM2(2), MYC(1), PIK3CA(29), PIK3R1(2), POLR1A(3), POLR1B(2), POLR1D(1), RAC1(1), RB1(12), TBX2(3), TP53(144) | 5471186 | 231 | 155 | 167 | 15 | 42 | 56 | 20 | 44 | 69 | 0 | 5.9e-11 | <1.00e-15 | <5.13e-14 |
| 3 | G2PATHWAY | Activated Cdc2-cyclin B kinase regulates the G2/M transition; DNA damage stimulates the DNA-PK/ATM/ATR kinases, which inactivate Cdc2. | ATM, ATR, BRCA1, CCNB1, CDC2, CDC25A, CDC25B, CDC25C, CDC34, CDKN1A, CDKN2D, CHEK1, CHEK2, EP300, GADD45A, MDM2, MYT1, PLK, PRKDC, RPS6KA1, TP53, WEE1, YWHAH, YWHAQ | 22 | ATM(8), ATR(13), BRCA1(12), CCNB1(2), CDC25B(2), CDC25C(1), CDKN1A(2), CHEK1(5), CHEK2(3), EP300(9), GADD45A(1), MDM2(2), MYT1(4), PRKDC(12), RPS6KA1(2), TP53(144), WEE1(4), YWHAQ(1) | 11369750 | 227 | 152 | 178 | 15 | 31 | 67 | 24 | 47 | 58 | 0 | 1.7e-09 | <1.00e-15 | <5.13e-14 |
| 4 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ABCB1(17), AKT1(1), ATM(8), BAX(1), CDKN1A(2), CPB2(3), CSNK1A1(2), CSNK1D(2), FHL2(1), GADD45A(1), HIF1A(1), IGFBP3(2), MAPK8(2), MDM2(2), NFKBIB(1), TP53(144) | 5574960 | 190 | 150 | 142 | 8 | 26 | 53 | 19 | 40 | 51 | 1 | 4.3e-11 | <1.00e-15 | <5.13e-14 |
| 5 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | APAF1(4), ATM(8), BAX(1), CCND1(1), CCNE1(3), CDKN1A(2), E2F1(2), GADD45A(1), MDM2(2), RB1(12), TP53(144) | 4870970 | 180 | 148 | 132 | 5 | 16 | 50 | 19 | 38 | 57 | 0 | 5.7e-12 | <1.00e-15 | <5.13e-14 |
| 6 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | ARF1(1), CCND1(1), CDKN1A(2), CDKN2A(26), CFL1(2), E2F1(2), MDM2(2), NXT1(1), PRB1(4), TP53(144) | 2299938 | 185 | 148 | 134 | 9 | 17 | 52 | 20 | 37 | 59 | 0 | 1.8e-11 | <1.00e-15 | <5.13e-14 |
| 7 | TELPATHWAY | Telomerase is a ribonucleotide protein that adds telomeric repeats to the 3' ends of chromosomes. | AKT1, BCL2, EGFR, G22P1, HSPCA, IGF1R, KRAS2, MYC, POLR2A, PPP2CA, PRKCA, RB1, TEP1, TERF1, TERT, TNKS, TP53, XRCC5 | 15 | AKT1(1), EGFR(7), IGF1R(1), MYC(1), POLR2A(2), PRKCA(5), RB1(12), TEP1(7), TERF1(3), TERT(3), TNKS(7), TP53(144), XRCC5(2) | 7526196 | 195 | 148 | 146 | 14 | 23 | 52 | 19 | 42 | 59 | 0 | 1.5e-09 | <1.00e-15 | <5.13e-14 |
| 8 | PLK3PATHWAY | Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. | ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH | 7 | ATM(8), ATR(13), CDC25C(1), CHEK1(5), CHEK2(3), TP53(144) | 4288732 | 174 | 146 | 126 | 6 | 17 | 48 | 21 | 37 | 51 | 0 | 1.8e-09 | <1.00e-15 | <5.13e-14 |
| 9 | PMLPATHWAY | Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. | CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 | 13 | CREBBP(17), DAXX(3), HRAS(4), PAX3(4), RARA(1), RB1(12), SIRT1(1), SP100(3), TNF(1), TNFRSF1A(2), TNFRSF1B(1), TP53(144) | 5147404 | 193 | 146 | 145 | 14 | 16 | 55 | 22 | 42 | 58 | 0 | 8.9e-09 | <1.00e-15 | <5.13e-14 |
| 10 | ATMPATHWAY | The tumor-suppressing protein kinase ATM responds to radiation-induced DNA damage by blocking cell-cycle progression and activating DNA repair. | ABL1, ATM, BRCA1, CDKN1A, CHEK1, CHEK2, GADD45A, JUN, MAPK8, MDM2, MRE11A, NBS1, NFKB1, NFKBIA, RAD50, RAD51, RBBP8, RELA, TP53, TP73 | 19 | ABL1(3), ATM(8), BRCA1(12), CDKN1A(2), CHEK1(5), CHEK2(3), GADD45A(1), JUN(3), MAPK8(2), MDM2(2), MRE11A(1), NFKB1(2), RAD50(3), RAD51(1), RBBP8(1), RELA(3), TP53(144) | 7989174 | 196 | 143 | 147 | 11 | 27 | 52 | 20 | 42 | 55 | 0 | 4.8e-09 | <1.00e-15 | <5.13e-14 |
Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HSA00627_1,4_DICHLOROBENZENE_DEGRADATION | Genes involved in 1,4-dichlorobenzene degradation | CMBL | 1 | CMBL(3) | 134924 | 3 | 3 | 3 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0.81 | 0.026 | 1 |
| 2 | HSA00902_MONOTERPENOID_BIOSYNTHESIS | Genes involved in monoterpenoid biosynthesis | CYP2C19, CYP2C9 | 2 | CYP2C19(8), CYP2C9(3) | 537026 | 11 | 10 | 11 | 3 | 5 | 3 | 0 | 2 | 1 | 0 | 0.55 | 0.13 | 1 |
| 3 | HSA00750_VITAMIN_B6_METABOLISM | Genes involved in vitamin B6 metabolism | AOX1, PDXK, PDXP, PNPO, PSAT1 | 5 | AOX1(13), PDXP(1), PSAT1(3) | 1297976 | 17 | 16 | 17 | 2 | 6 | 5 | 0 | 5 | 1 | 0 | 0.13 | 0.15 | 1 |
| 4 | SA_G2_AND_M_PHASES | Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition. | CDC2, CDC25A, CDC25B, CDK7, CDKN1A, CHEK1, NEK1, WEE1 | 7 | CDC25B(2), CDK7(1), CDKN1A(2), CHEK1(5), NEK1(3), WEE1(4) | 1922578 | 17 | 17 | 17 | 1 | 7 | 5 | 1 | 3 | 1 | 0 | 0.1 | 0.23 | 1 |
| 5 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(2) | 192952 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0.5 | 0.27 | 1 |
| 6 | P27PATHWAY | p27 blocks the G1/S transition by inhibiting the checkpoint kinase cdk2/cyclin E and is inhibited by cdk2-mediated ubiquitination. | CCNE1, CDK2, CDKN1B, CKS1B, CUL1, E2F1, NEDD8, RB1, RBX1, SKP1A, SKP2, TFDP1, UBE2M | 11 | CCNE1(3), CKS1B(1), CUL1(4), E2F1(2), RBX1(1), SKP2(2), TFDP1(3), UBE2M(1) | 1828772 | 17 | 16 | 17 | 1 | 5 | 8 | 0 | 2 | 2 | 0 | 0.05 | 0.29 | 1 |
| 7 | FBW7PATHWAY | Cyclin E interacts with cell cycle checkpoint kinase cdk2 to allow transcription of genes required for S phase, including transcription of additional cyclin E. | CCNE1, CDC34, CDK2, CUL1, E2F1, FBXW7, RB1, SKP1A, TFDP1 | 7 | CCNE1(3), CUL1(4), E2F1(2), FBXW7(11), TFDP1(3) | 1763624 | 23 | 23 | 21 | 4 | 6 | 8 | 3 | 1 | 5 | 0 | 0.25 | 0.32 | 1 |
| 8 | HSA00550_PEPTIDOGLYCAN_BIOSYNTHESIS | Genes involved in peptidoglycan biosynthesis | GLUL, PGLYRP2 | 2 | GLUL(4), PGLYRP2(2) | 488788 | 6 | 5 | 6 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0.15 | 0.32 | 1 |
| 9 | HSA00780_BIOTIN_METABOLISM | Genes involved in biotin metabolism | BTD, HLCS, SPCS1, SPCS3 | 4 | BTD(2), HLCS(5), SPCS1(1), SPCS3(2) | 826632 | 10 | 9 | 10 | 2 | 2 | 2 | 2 | 0 | 4 | 0 | 0.4 | 0.41 | 1 |
| 10 | IL18PATHWAY | Pro-inflammatory IL-18 is activated in macrophages by caspase-1 cleavage and, in conjunction with IL-12, stimulates Th1 cell differentiation. | CASP1, IFNG, IL12A, IL12B, IL18, IL2 | 6 | CASP1(1), IFNG(1), IL12A(1), IL12B(3) | 802958 | 6 | 6 | 6 | 1 | 3 | 1 | 0 | 0 | 2 | 0 | 0.52 | 0.48 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.